Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 8/20 | 0.36 |
| ▸ | NPC1 | O15118 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881051 | 0.91 | RAB9A (0.38) | KMT2AKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL4881302 | 0.91 | KMT2A (0.38) | KMT2AKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL4880879 | 0.86 | RAB9A (0.37) | KMT2AKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL4881687 | 0.86 | SIRT2 (0.37) | KMT2AKDM4ERXFP1MAPTRAB9A | |
| SCHEMBL4880731 | 0.84 | MAPT (0.36) | KDM4EMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4881605 | 0.83 | KMT2A (0.43) | KMT2AKDM4ERXFP1MAPTRAB9A | |
| SCHEMBL4885688 | 0.80 | RAB9A (0.35) | KMT2AKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3614731 | 0.80 | RAB9A (0.39) | KMT2AKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL4876097 | 0.77 | F10 (0.38) | KMT2AKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL4886038 | 0.76 | KMT2A (0.40) | KMT2AMAPTRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1819701-A1 | CYCLIC IMINOCARBAMATES AND USE THEREOF | Bayer HealthCare AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058630-A1 | CYCLIC IMINOCARBAMATES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | F2, UQCRB, F12 | KMT2A 3720/4885KDM4E 3856/4885RXFP1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.